Approval of the First Dengue Vaccine in India | 2026 [rdxzBMbxK00]
Approval of the First Dengue Vaccine in India * Overview of the Vaccine - The Drug Controller General of India has granted market authorization to Takeda Biopharmaceuticals India for the vaccine known as QDENGA, also referred to as TAK-003. - This marks the first time a dengue vaccine has received approval for use within India. - The vaccine is indicated for the prevention of dengue in individuals ranging from 4 to 60 years of age. * Vaccine Characteristics and Administration - QDENGA is a live-attenuated tetravalent vaccine engineered to protect against all 4 dengue virus serotypes, specifically dengue virus 1 through dengue virus 4. - The immunization protocol consists of a 2-dose regimen, with the doses administered 3 months apart. - Patients do not require pre-vaccination screening, and the vaccine is effective regardless of whether an individual has experienced a previous dengue infection. - The vaccine has secured regulatory approval in over 40 countries, including the European Union, the United Kingdom, Brazil, Indonesia, and Argentina. * Understanding Dengue Disease - Dengue is a mosquito-borne tropical disease caused by the dengue virus, which typically results in mild, flu-like symptoms. - In some cases, patients may develop severe disease characterized by potentially fatal bleeding and organ damage. - The disease is a major global public health threat, affecting more than 125 countries. - India currently accounts for nearly one-third of the total global dengue burden. 👍 Like | 📢 Share | 🔔 Subscribe 📌 Watch more content here: